These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8647363

  • 1. [-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-].
    Nagele E, Kurz C, Speiser P, Vavra N, Sevelda P.
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):79-82. PubMed ID: 8647363
    [Abstract] [Full Text] [Related]

  • 2. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
    van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R.
    Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
    van Dalen A, Favier J, Baumgartner L, Hasholzner U, de Bruijn H, Dobbler D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Einarsson R.
    Anticancer Res; 1999 Dec; 19(4A):2523-6. PubMed ID: 10470187
    [Abstract] [Full Text] [Related]

  • 5. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M.
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE.
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [Abstract] [Full Text] [Related]

  • 9. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY, Ye J, Feng SW, Lü WG, Wan XY, Xie X.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F, Vavra N, Kurz C, Sevelda P.
    Wien Klin Wochenschr; 1993 Nov; 105(20):585-8. PubMed ID: 8259686
    [Abstract] [Full Text] [Related]

  • 13. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Acta Obstet Gynecol Scand; 2008 Nov; 87(11):1136-42. PubMed ID: 18951217
    [Abstract] [Full Text] [Related]

  • 14. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK, Nørgaard-Pedersen B, Mogensen O.
    Anticancer Res; 2002 Nov; 22(3):1765-8. PubMed ID: 12168866
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 16. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM, Bufe A, Kümper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K, Burges A.
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.